Vigilant Technology raises GBP10 million in UK IPO

Vigilant, which is based in Tel Aviv and develops CCTV (closed circuit TV) security and surveillance systems, said it was issuing 23.3 million new shares at 43 pence each, which will start trading on Tuesday.

By YIGAL GRAYEFF
December 20, 2005 07:57
2 minute read.
vigilant logo 88

vigilant logo 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Vigilant Technology has raised GBP10 million in its initial public offering on the Alternative Investment Market of the London Stock Exchange. The company was one of three to disclose information about new listings on Monday, with Nasdaq-traded Camtek saying it plans to register its shares in Tel Aviv and NasVax saying it was delaying its IPO until Thursday. Vigilant, which is based in Tel Aviv and develops CCTV (closed circuit TV) security and surveillance systems, said it was issuing 23.3 million new shares at 43 pence each, which will start trading on Tuesday. Vigilant intends to use proceeds from the sale to fund the expansion of its sales and marketing department. Vigilant will have a market capitalization of about GBP24.3m following the offering. Also, the company said it appointed Trevor Chinn as its chairman. Chinn is chairman of the AA, a UK breakdown company, and is co-chairman of the Israel-Britain Business Council. Vigilant develops hardware and software for recording and analyzing digital video footage collected from a large number of security cameras, with customers including Ben Gurion Airport and a number of London municipalities. The company was founded in 1999 by two brothers, Yoram and Ronen Sagher, together with Adi Pinhas who left three years ago. In 2004, it recorded a net loss of $900,000 on sales of $6.2m., although analysts believe the company will have a net profit of $500,000 on sales of $8m. to $10m. in 2005, a spokeswoman said. Meanwhile, Migdal Ha'emek-based Camtek has applied to list its shares on the Tel Aviv Stock Exchange and expects the shares to start trading on Wednesday. The company, which develops optical inspection systems for printed circuit boards, believes the dual-listing will facilitate trading in Israel by lowering transaction costs for Israeli investors and giving them greater access to the shares. The company is worth $115m. and expects to be included in the Tel Aviv 100 and Tel Tec indexes. Finally, NasVax, which develops flu vaccines, was supposed to start trading on Monday but delayed its IPO until Thursday due to uncertain market conditions before the opening of trade. Chief executive Itzik Goldwaser declined to comment on what caused the uncertainty, but the announcement came hours after Prime Minister Ariel Sharon suffered a minor stroke. NasVax, which was founded in August last year, is planning to issue 7.1 million shares at NIS 4.54 each and to raise NIS 16m. in bonds.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS